Last edition
News about "China drug approval"
HUTCHMED Secures NMPA Approval for ORPATHYS in Gastric Cancer
HUTCHMED has received NMPA approval for ORPATHYS, the first selective MET inhibitor in China for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma.
China Drug Approval | 04/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members